Buy Rating Affirmed for BioCryst Pharmaceuticals on Orladeyo's Success and Strong Growth Prospects
Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target
BioCryst Pharma Analyst Ratings
JP Morgan Reinstates Overweight on BioCryst Pharma, Announces $10 Price Target
BioCryst Pharma Analyst Ratings
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
BioCryst Pharmaceuticals' Promising Pipeline and Undervalued Stock: A Buy Rating Analysis
BioCryst Pharma Analyst Ratings
RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $10 Price Target
BioCryst Pharma Analyst Ratings
RBC Capital Upgrades BioCryst Pharma to Outperform, Raises Price Target to $10
BioCryst Pharma Analyst Ratings
RBC Capital Maintains Sector Perform on BioCryst Pharma, Raises Price Target to $9
Jefferies Upgrades BioCryst Pharma to Buy, Announces $11 Price Target
HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target
BioCryst Pharma Analyst Ratings
Needham Reiterates Buy on BioCryst Pharma, Lowers Price Target to $12
BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings
RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating
No Data